Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial.

João Sérgio Neves,Francisco Vasques-Nóvoa,Marta Borges-Canha,Ana Rita Leite,Abhinav Sharma,Davide Carvalho,Milton Packer,Faiez Zannad,Adelino Leite-Moreira,João Pedro Ferreira

Diabetes, obesity & metabolism（2023）

引用 6|浏览42

暂无评分

摘要

In patients with HFrEF, liraglutide might increase the risk of cardiovascular adverse effects, an effect possibly driven by excess risk of arrhythmias and worsening HF events. As this was a post hoc analysis, these results should be interpreted as exploratory and hypothesis-generating. Further RCTs must be conducted before drawing definitive conclusions.

查看译文

关键词

GLP-1 receptor agonists,adverse events,arrhythmia,heart failure hospitalizations,heart failure with reduced ejection fraction,liraglutide

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要